Investors applaud Salix acquisition

Posted on November 8, 2013 

Wall Street gave a huge thumbs-up to Salix Pharmaceuticals’ plan to acquire specialty drug company Santarus for $2.6 billion.

Shares of Raleigh-based Salix rose 18 percent Friday, closing at $84, following the news of the deal, which was announced Thursday after the markets closed. Salix shares have doubled in value this year.

Combining the two businesses will give Salix a portfolio of 22 drugs that treat gastrointestinal ailments of annual revenue of nearly $1.35 billion.

Santarus’ drugs include a treatment for ulcerative colitis, Uceris, and the heartburn treatment Zegerid.

Investors also may have been motivated by Salix’s third-quarter earnings report. The company’s net income handily exceeded the consensus projection of analysts who cover the company and revenue rose 29 percent to $238.2 million.

Staff writer David Ranii

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service